透析高危患者长期异烟肼预防结核的安全性与有效性
该研究在南非高结核负担地区对182例接受透析的CKD-5D患者实施普遍长期异烟肼预防治疗(IPT),并与同一单位111例历史队列比较。结果显示IPT使结核发病率从4505/10万人年降至367/10万人年(相对风险下降92%,P<0.001),不良反应多为轻度和可逆,仅9.3%因副作用停药,无IPT相关死亡。
要点
- 长期IPT使透析患者结核发病率相对下降92%(P<0.001)。
- 周围神经病变发生率17.6%,多数经增加吡哆醇剂量后完全缓解。
- 因副作用停用IPT者占9.3%,无IPT相关死亡。
核心结论
- 长期异烟肼预防治疗可显著降低CKD-5D透析高危人群的结核发病率,且安全性和耐受性良好。
研究设计与样本
- 2019—2025年在南非Gqeberha高结核负担地区对182例CKD-5D透析患者实施普遍长期IPT(post-IPT队列),并与同一单位111例历史CKD-5D队列(pre-IPT)比较。
主要发现
- post-IPT队列结核发病率为367/10万人年,pre-IPT队列为4505/10万人年,相对风险下降92%(P<0.001)。
- IPT期间32例(17.6%)出现周围神经病变症状,其中20例(62.5%)经增加吡哆醇剂量后完全缓解。
- 周围神经病变与年龄较大和血液透析相关;肝损伤6例(3.3%),其中2例继续IPT成功。
- 17例(9.3%)因IPT相关副作用停药(周围神经病变12例、肝损伤4例、胰腺炎1例),无死亡归因于IPT。
临床怎么用
- 在高结核负担地区,可考虑对CKD-5D透析患者实施长期IPT以降低结核发病风险。
- IPT期间应监测周围神经病变与肝损伤,必要时增加吡哆醇剂量或停药。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with chronic kidney disease (CKD) receiving dialysis (CKD-5D) are at increased risk for tuberculosis (TB), which significantly heightens the risk of mortality. Long-term isoniazid prevention therapy (IPT) to prevent TB is a promising strategy, although the safety and effectiveness of the approach in this high-risk population is unknown. METHODS: Between 2019 and 2025, universal long-term IPT was administered to patients with CKD-5D (N = 182) receiving dialysis in Gqeberha, South Africa (post-IPT cohort), an area with high TB rates. The incidence of TB post-IPT was compared with a historical CKD-5D cohort (pre-IPT) from the same unit (n = 111). Primary outcomes included incident TB and adverse events attributable to IPT. RESULTS: The incidence of TB (per 100,000 person-years [pys]) in the post-IPT cohort was 367, versus 4505 pre-IPT (92% relative risk reduction, P < 0.001). During IPT, 32 patients (17.6%) developed symptoms of peripheral neuropathy (PNP), of whom 20 (62.5%) resolved fully with increased pyridoxine dosing. PNP was associated with older age and hemodialysis (HD). Liver injury was noted in 6 patients (3.3%), of whom 2 continued IPT successfully. Overall, 17 patients (9.3%) required discontinuation of IPT because of side effects attributed to IPT (PNP = 12, liver injury = 4, and pancreatitis = 1). No deaths were attributed to IPT. CONCLUSION: Long-term IPT significantly reduced the incidence of TB in a high-risk cohort with CKD-5D. IPT was safe and well-tolerated, with < 10% of patients discontinuing therapy because of adverse events, which were generally mild and reversible. These findings provide strong real-world evidence supporting IPT use in TB-endemic dialysis populations.
引用
- Freercks R, Manning K, Ensor J, et al. Safety and Effectiveness of Long-Term Isoniazid Treatment for the Prevention of Tuberculosis in High-Risk Dialysis Patients. Kidney Int Rep. 2025. PMID: 41550517. doi:10.1016/j.ekir.2025.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。